Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Myelodysplastic Syndrome
NCT00225992Phase 2Terminated
- Sponsor
- Oncology Specialties
- Start
- Feb 2004
- Primary completion
- Nov 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in myelodysplastic syndrome (MDS), sponsored by Oncology Specialties. Started Feb 2004; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00225992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225992.